MA33917B1 - Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue - Google Patents
Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitueInfo
- Publication number
- MA33917B1 MA33917B1 MA35055A MA35055A MA33917B1 MA 33917 B1 MA33917 B1 MA 33917B1 MA 35055 A MA35055 A MA 35055A MA 35055 A MA35055 A MA 35055A MA 33917 B1 MA33917 B1 MA 33917B1
- Authority
- MA
- Morocco
- Prior art keywords
- cycle
- carboxylic acid
- acid derivatives
- substituted oxazolopyrimidine
- oxazolopyrimidine
- Prior art date
Links
- BRIOKNPDCPJCOD-UHFFFAOYSA-N [1,3]oxazolo[5,4-d]pyrimidine Chemical class N1=CN=C2OC=NC2=C1 BRIOKNPDCPJCOD-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des composés d'oxazolopyrimidine de la formule (i) dans laquelle a, r1, r2, r3 et x sont définis comme indiqués dans les revendications. Les composés de la formule (i) conviennent par exemple pour la cicatrisation de plaies.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305042 | 2010-01-14 | ||
| PCT/EP2011/050301 WO2011086079A1 (fr) | 2010-01-14 | 2011-01-12 | Dérivés d'acide carboxylique comprenant un noyau d'oxazolopyrimidine à substitution en 2,5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33917B1 true MA33917B1 (fr) | 2013-01-02 |
Family
ID=41800578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35055A MA33917B1 (fr) | 2010-01-14 | 2011-01-12 | Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8846692B2 (fr) |
| EP (1) | EP2523962B1 (fr) |
| JP (1) | JP5841067B2 (fr) |
| KR (1) | KR101759128B1 (fr) |
| CN (1) | CN102791717B (fr) |
| AR (1) | AR079997A1 (fr) |
| AU (1) | AU2011206615B2 (fr) |
| BR (1) | BR112012017437B1 (fr) |
| CA (1) | CA2784560C (fr) |
| CL (1) | CL2012001972A1 (fr) |
| CO (1) | CO6612239A2 (fr) |
| CY (1) | CY1115055T1 (fr) |
| DK (1) | DK2523962T3 (fr) |
| ES (1) | ES2441954T3 (fr) |
| HR (1) | HRP20140179T1 (fr) |
| IL (1) | IL220720A (fr) |
| MA (1) | MA33917B1 (fr) |
| MX (1) | MX2012007834A (fr) |
| MY (1) | MY156550A (fr) |
| NZ (1) | NZ601113A (fr) |
| PH (1) | PH12012501265A1 (fr) |
| PL (1) | PL2523962T3 (fr) |
| PT (1) | PT2523962E (fr) |
| RS (1) | RS53254B (fr) |
| RU (1) | RU2564018C2 (fr) |
| SG (1) | SG182484A1 (fr) |
| SI (1) | SI2523962T1 (fr) |
| TW (1) | TWI510242B (fr) |
| UY (1) | UY33179A (fr) |
| WO (1) | WO2011086079A1 (fr) |
| ZA (1) | ZA201204174B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI478929B (zh) | 2010-01-13 | 2015-04-01 | Sanofi Aventis | 含２，５，７－經取代唑并嘧啶環之羧酸衍生物 |
| UY33176A (es) | 2010-01-13 | 2011-08-31 | Sanofi Aventis | Derivados de oxazolopirimidina sustituida en 2, 5, 7. |
| SG182474A1 (en) * | 2010-01-14 | 2012-08-30 | Sanofi Sa | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring |
| TWI544926B (zh) | 2010-01-14 | 2016-08-11 | 賽諾菲阿凡提斯公司 | ２，５－經取代之唑并嘧啶衍生物類 |
| US9321787B2 (en) * | 2011-07-07 | 2016-04-26 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring |
| EP2862574A1 (fr) * | 2013-10-15 | 2015-04-22 | Sanofi | Acide {4-[5-(3-chloro-phénoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-diméthyl-phénoxy}-acétique pour son utilisation dans la prévention ou le traitement de l'insuffisance rénale aiguë |
| CN118697873B (zh) * | 2023-03-27 | 2026-05-12 | 四川大学华西医院 | S1pr1偏向性激动剂在制备治疗炎症性肠病的药物中的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3679682A (en) * | 1970-04-23 | 1972-07-25 | Fmc Corp | CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES |
| JPH01242587A (ja) * | 1988-03-25 | 1989-09-27 | Sankyo Co Ltd | 縮環オキサゾロチエノピリミジン誘導体 |
| WO2004096813A1 (fr) * | 2003-04-25 | 2004-11-11 | University College Cardiff Consultants Limited | Composes heterocycliques destines a etre utilises dans le traitement d'infections virales |
| AU2004234067B2 (en) * | 2003-04-30 | 2008-02-28 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
| EP1628967B1 (fr) * | 2003-05-19 | 2014-04-09 | Irm Llc | Composés immunosuppresseurs et compositions |
| AU2004240649A1 (en) * | 2003-05-19 | 2004-12-02 | Irm, Llc | Immunosuppressant compounds and compositions |
| CN101291908A (zh) * | 2005-08-23 | 2008-10-22 | Irm责任有限公司 | 免疫抑制剂化合物和组合物 |
| AU2007227278B2 (en) * | 2007-03-21 | 2014-09-11 | Epix Pharmaceuticals, Inc. | SIP receptor modulating compounds and use thereof |
| TW201000099A (en) * | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
| EP2318415B1 (fr) * | 2008-07-15 | 2013-02-20 | Sanofi | Oxazolopyrimidines comme agonistes du récepteur edg-1 |
| AR079982A1 (es) * | 2010-01-13 | 2012-03-07 | Sanofi Aventis | Derivados de acido carboxilico heterociclicos que comprenden un anillo de oxazolopirimidina 2,5,7- sustituido., composiciones farmaceuticas y procesos para prepararlos. |
| UY33176A (es) * | 2010-01-13 | 2011-08-31 | Sanofi Aventis | Derivados de oxazolopirimidina sustituida en 2, 5, 7. |
| TWI478929B (zh) * | 2010-01-13 | 2015-04-01 | Sanofi Aventis | 含２，５，７－經取代唑并嘧啶環之羧酸衍生物 |
| SG182474A1 (en) * | 2010-01-14 | 2012-08-30 | Sanofi Sa | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring |
| TWI544926B (zh) * | 2010-01-14 | 2016-08-11 | 賽諾菲阿凡提斯公司 | ２，５－經取代之唑并嘧啶衍生物類 |
-
2011
- 2011-01-12 JP JP2012548410A patent/JP5841067B2/ja active Active
- 2011-01-12 PH PH1/2012/501265A patent/PH12012501265A1/en unknown
- 2011-01-12 AR ARP110100092A patent/AR079997A1/es active IP Right Grant
- 2011-01-12 MA MA35055A patent/MA33917B1/fr unknown
- 2011-01-12 UY UY0001033179A patent/UY33179A/es not_active Application Discontinuation
- 2011-01-12 NZ NZ601113A patent/NZ601113A/xx unknown
- 2011-01-12 WO PCT/EP2011/050301 patent/WO2011086079A1/fr not_active Ceased
- 2011-01-12 CN CN201180013877.9A patent/CN102791717B/zh active Active
- 2011-01-12 SI SI201130094T patent/SI2523962T1/sl unknown
- 2011-01-12 MY MYPI2012002588A patent/MY156550A/en unknown
- 2011-01-12 US US13/521,831 patent/US8846692B2/en active Active
- 2011-01-12 DK DK11700404.4T patent/DK2523962T3/en active
- 2011-01-12 KR KR1020127021242A patent/KR101759128B1/ko active Active
- 2011-01-12 HR HRP20140179AT patent/HRP20140179T1/hr unknown
- 2011-01-12 SG SG2012051405A patent/SG182484A1/en unknown
- 2011-01-12 RS RS20140062A patent/RS53254B/sr unknown
- 2011-01-12 AU AU2011206615A patent/AU2011206615B2/en active Active
- 2011-01-12 TW TW100101053A patent/TWI510242B/zh active
- 2011-01-12 MX MX2012007834A patent/MX2012007834A/es active IP Right Grant
- 2011-01-12 EP EP11700404.4A patent/EP2523962B1/fr active Active
- 2011-01-12 CA CA2784560A patent/CA2784560C/fr active Active
- 2011-01-12 PL PL11700404T patent/PL2523962T3/pl unknown
- 2011-01-12 BR BR112012017437-1A patent/BR112012017437B1/pt active IP Right Grant
- 2011-01-12 ES ES11700404.4T patent/ES2441954T3/es active Active
- 2011-01-12 RU RU2012134630/04A patent/RU2564018C2/ru active
- 2011-01-12 PT PT117004044T patent/PT2523962E/pt unknown
-
2012
- 2012-06-07 ZA ZA2012/04174A patent/ZA201204174B/en unknown
- 2012-07-02 IL IL220720A patent/IL220720A/en active IP Right Grant
- 2012-07-13 CL CL2012001972A patent/CL2012001972A1/es unknown
- 2012-07-26 CO CO12125684A patent/CO6612239A2/es unknown
-
2014
- 2014-01-30 CY CY20141100079T patent/CY1115055T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31574B1 (fr) | Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf | |
| MA31710B1 (fr) | (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament | |
| MA37519B1 (fr) | Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 | |
| MA32468B1 (fr) | Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k | |
| TN2013000353A1 (fr) | Dérivés de fluoro-pyridinone utiles comme agents antibactériens | |
| MA33275B1 (fr) | Inhibiteurs de la replication du virus de l'immunodeficience humaine | |
| MA33492B1 (fr) | Inhibiteurs de bace | |
| MA34397B1 (fr) | Dérivés d'acide napht-2-ylacétique dans le traitement du sida | |
| MA32351B1 (fr) | Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer | |
| EA200601830A1 (ru) | Ортозамещённые арильные или гетероарильные амидные соединения | |
| MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
| MA35434B1 (fr) | Amino-quinazolines en tant qu'inhibiteurs de kinase | |
| MA35132B1 (fr) | 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine | |
| MA33358B1 (fr) | Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase | |
| EA201490493A1 (ru) | Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы | |
| EA201390222A1 (ru) | Гетероциклическое соединение и его применение | |
| MX2012000441A (es) | Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer. | |
| UA107652C2 (en) | Carbazole compounds and therapeutic uses of the compounds | |
| MX2009011865A (es) | Tratamiento de lesiones viralmente inducidas. | |
| MA37891B1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| MX2012002641A (es) | Inhibidores de cinasa janus (jak). | |
| EA201171211A1 (ru) | Производные оксадиазола | |
| EA200802054A1 (ru) | Ингибиторы фермента | |
| EP2519512A4 (fr) | La présente invention concerne le domaine des N1-acyl-5-fluoropyrimidinones et de leurs dérivés et sur l'utilisation de ses composés comme fongicides | |
| MA32173B1 (fr) | Derives de pyridin-2-yle utilises comme agents immunomodulateurs |